Leukotriene receptors: Crucial components in vascular inflammation

TheScientificWorldJournal

Volumn 7, Issue , 2007, Pages 1422-1439

  Bäck, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Eicosanoids; Endothelium; Intimal hyperplasia; Leukotriene receptor antagonists; Lipoxygenase; Vascular smooth muscle cells

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; BIIL 284; CYSTEINE LEUKOTRIENE RECEPTOR ANTAGONIST; ICI 1986153; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUKOTRIENE RECEPTOR STIMULATING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; U 75303; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; LEUKOTRIENES; LIPOXYGENASE; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, LEUKOTRIENE; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VASCULITIS;

EID: 34548746511     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2007.187     Document Type: Review

References (127)

1. Brink, C. (2007) Structural manipulation of eicosanoid receptors and cellular signaling. TheScientificWorldJOURNAL 7, 1285-1306.
2. Brink, C., Dahlén, S.E., Drazen, J., Evans, J.F., Hay, D.W., Nicosia, S., Serhan, C.N., Shimizu, T., and Yokomizo, T. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227.
3. 4: metabolism and signal transduction. Arch. Biochem. Biophys. 385, 231-241.
4. Bäck, M. (2002) Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 71, 611-622.
5. Brock, T.G. and Peters-Golden, M. (2007) Activation and regulation of cellular eicosanoid biosynthesis. TheScientificWorldJOURNAL 7, 1273-1284.
6. Zhang, Y.Y., Walker, J.L., Huang, A., Keaney, J.F., Clish, C.B., Serhan, C.N., and Loscalzo, J. (2002) Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem. J. 361, 267-276.
7. 1 receptor via intracellular calcium mobilization in smooth muscle cells. Br. J. Pharmacol. 138, 707-715.
8. Spanbroek, R., Gräbner, R., Lötzer, K., Hildner, M., Urbach, A., Rühling, K., Moos, M.P., Kaiser, B., Cohnert, T.U., Wahlers, T., Zieske, A., Plenz, G., Robenek, H., Salbach, P., Kühn, H., Rådmark, O., Samuelsson, B., and Habenicht, A.J. (2003) Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 100, 1238-1243.
9. Cipollone, F., Mezzetti, A., Fazia, M.L., Cuccurullo, C., Iezzi, A., Ucchino, S., Spigonardo, F., Bucci, M., Cuccurullo, F., Prescott, S.M., and Stafforini, D.M. (2005) Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 25, 1665-1670.
10. Bäck, M., Sultan, A., Ovchinnikova, O., and Hansson, G.K. (2007) 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946-949.
11. Robertson, A.K., Rudling, M., Zhou, X., Gorelik, L., Flavell, R.A., and Hansson, G.K. (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350.
12. Kim, N. and Luster, A. (2007) Regulation of immune cells by eicosanoid receptors. TheScientificWorldJOURNAL 7, 1307-1328.
13. 4 production in human atherosclerotic plaques. Biomed. Biochim. Acta 47, S182-185.
14. Piomelli, D., Feinmark, S.J., and Cannon, P.J. (1987) Leukotriene biosynthesis by canine and human coronary arteries. J. Pharmacol. Exp. Ther. 241, 763-770.
15. Carry, M., Korley, V., Willerson, J.T., Weigelt, L., Ford-Hutchinson, A.W., and Tagari, P. (1992) Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 85, 230-236.
16. 4 in coronary artery disease and after coronary artery bypass surgery. Coron. Artery. Dis. 4, 899-904.
17. Bäck, M., Airila-Månsson, S., Jogestrand, T., Söder, B., and Söder, P.O. (2007) Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis 193, 389-394.
18. Bäck, M. and Hansson, G.K. (2006) Leukotriene receptors in atherosclerosis. Ann. Med. 38, 493-502.
19. 4 - a stereospecific stimulator for release of lysosomal enzymes from neutrophils. FEBS Lett. 130, 146-148.
20. 4 receptor antagonist CP-105696. J. Pharmacol. Exp. Ther. 273, 176-184.
21. 4 that mediates chemotaxis. Nature 387, 620-624.
22. 2: a new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-431.
23. 4 receptor. Biochem. Biophys. Res. Commun. 274, 377-382.
24. 4 receptor. J. Biol. Chem. 275, 27000-27004.
25. 4 receptor. Cloning and functional characterization. J. Biol. Chem. 275, 40686-40694.
26. 4 receptors in human mononuclear cells. Life Sci. 68, 2207-2212.
27. 4 pathway to inflammation control. Nature 384, 39-43.
28. 1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 102, 17501-17506.
29. 1 in smooth muscle cell recruitment. Circulation 112, 578-586.
30. Valen, G., Yan, Z.Q., and Hansson, G.K. (2001) Nuclear factor kappa-B and the heart. J. Am. Coll. Cardiol. 38, 307-314.
31. Bu, D.X., Erl, W., de Martin, R., Hansson, G.K., and Yan, Z.Q. (2005) IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J. 19, 1293-1295.
32. 4 receptor gene. J. Exp. Med. 192, 421-431.
33. 1, in human monocytes. J. Leukoc. Biol. 77, 1018-1025.
34. 4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem. Biophys. Res. Commun. 309, 114-119.
35. Benjamim, C.F., Canetti, C., Cunha, F.Q., Kunkel, S.L., and Peters-Golden, M. (2005) Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J. Immunol. 174, 1616-1620.
36. 4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. Am. J. Physiol. Heart Circ. Physiol. 287, H419-H424.
37. 1 receptor. Nature 399, 789-793.
38. Sarau, H.M., Ames, R.S., Chambers, J., Ellis, C., Elshourbagy, N., Foley, J.J., Schmidt, D.B., Muccitelli, R.M., Jenkins, O., Murdock, P.R., Herrity, N.C., Halsey, W., Sathe, G., Muir, A.I., Nuthulaganti, P., Dytko, G.M., Buckley, P.T., Wilson, S., Bergsma, D.J., and Hay, D.W. (1999) Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56, 657-663.
39. Heise, C.E., O'Dowd, B.F., Figueroa, D.J., Sawyer, N., Nguyen, T., Im, D.S., Stocco, R., Bellefeuille, J.N., Abramovitz, M., Cheng, R., Williams, D.L., Zeng, Z., Liu, Q., Ma, L., Clements, M.K., Coulombe, N., Liu, Y., Austin, C.P., George, S.R., O'Neill, G.P., Metters, K.M., Lynch, K.R., and Evans, J.F. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30531-30536.
40. 2 receptor. Biochem. Biophys. Res. Commun. 274, 316-322.
41. Nothacker, H.P., Wang, Z., Zhu, Y., Reinscheid, R.K., Lin, S.H., and Civelli, O. (2000) Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol. 58, 1601-1608.
42. Dahlén, S.-E. and Bäck, M. (2001) Leukotriene receptors: functional aspects and future targets. Clin. Exp. Allergy. Rev. 1, 137-141.
43. Dahlén, S.E. (2006) Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur. J. Pharmacol. 533, 40-56.
44. Labat, C., Ortiz, J.L., Norel, X., Gorenne, I., Verley, J., Abram, T.S., Cuthbert, N.J., Tudhope, S.R., Norman, P., Gardiner, P., and Brink, C. (1992) A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 263, 800-805.
45. Allen, S.P., Chester, A.H., Dashwood, M.R., Tadjkarimi,.S., Piper, P.J., and Yacoub, M.H. (1994) Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implications for graft performance. Circulation 90, 515-524.
46. 4. Cardioscience 4, 47-54.
47. Mechiche, H., Candenas, L., Pinto, F.M., Nazeyrollas, P., Clement, C., and Devillier, P. (2004) Characterization of cysteinyl leukotriene receptors on human saphenous veins: antagonist activity of montelukast and its metabolites. J. Cardiovasc. Pharmacol. 43, 113-120.
48. Bäck, M., Norel, X., Walch, L., Gascard, J., de Montpreville, V., Dahlén, S., and Brink, C. (2000) Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur. J. Pharmacol. 401, 389-395.
49. Walch, L., Norel, X., Bäck, M., Gascard, J.P., Dahlén, S.E., and Brink, C. (2002) Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br. J. Pharmacol. 137, 1339-1345.
50. Bäck, M., Norel, X., Walch, L., Gascard, J., Mazmanian, G., Dahlén, S., and Brink, C. (2000) Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. Eur. J. Pharmacol. 401, 381-388.
51. Sakata, K. and Bäck, M. (2002) Receptor preferences of cysteinyl-leukotrienes in the guinea pig lung parenchyma. Eur. J. Pharmacol. 436, 119-126.
52. Hardy, G., Stanke-Labesque, F., Peoc'h, M., Hakim, A., Devillier, P., Caron, F., Morel, S., Faure, P., Halimi, S., and Bessard, G. (2001) Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocininduced diabetic rats. Arterioscler. Thromb. Vasc. Biol. 21, 1751-1758.
53. 1 antagonists and counteracted by prostacyclin release. Adv. Exp. Med. Biol. 507, 315-319.
54. Woszczek, G., Pawliczak, R., Qi, H.Y., Nagineni, S., Alsaaty, S., Logun, C., and Shelhamer, J.H. (2005) Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J. Immunol. 175, 5152-5159.
55. 4 and regulation of vascular and inflammatory responses. Am J Pathol 158, 3-9.
56. Lötzer, K., Spanbroek, R., Hildner, M., Urbach, A., Heller, R., Bretschneider, E., Galczenski, H., Evans, J.F., and Habenicht, A.J. (2003) Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 23, e32-e36.
57. 2. J. Biol. Chem. 276, 12454-12459.
58. 4 myotropic activity by the 2,6 disubstituted pyridine analog U-75302: characterization on lung parenchyma strips. J. Lipid Mediat. 1, 3-12.
59. 4 in the guinea-pig lung involves a vascular component. Br. J. Pharmacol. 141, 449-456.
60. Hwang, S.W., Cho, H., Kwak, J., Lee, S.Y., Kang, C.J., Jung, J., Cho, S., Min, K.H., Suh, Y.G., Kim, D., and Oh, U. (2000) Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U. S. A. 97, 6155-6160.
61. 4. Biochem. Biophys. Res. Commun. 237, 413-418.
62. 2 receptor on human coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 287, 1088-1092.
63. 4. Prostaglandins Other Lipid Mediat. 83, 209-212.
64. Schellenberg, R.R. and Foster, A. (1984) Differential activity of leukotrienes upon human pulmonary vein and artery. Prostaglandins, 27, 475-482.
65. Stanke-Labesque, F., Devillier, P., Bedouch, P., Cracowski, J.L., Chavanon, O., and Bessard, G. (2000) Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition. Cardiovasc. Res. 47, 376-283.
66. 4-induced homologous desensitization of calcium mobilization and phosphoinositide metabolism in U-937 cells. J. Pharmacol. Exp. Ther., 246, 204-210.
67. 1) is crucial for ligand-induced, Gprotein-coupled receptor-specific kinase 6-mediated desensitization. J. Biol. Chem. 277, 31567-31576.
68. Dahlén, S.E., Björk, J., Hedqvist, P., Arfors, K.E., Hammarström, S., Lindgren, J.A., and Samuelsson, B. (1981) Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 78, 3887-3891.
69. Trandafir, C.C., Nishihashi, T., Ji, X., Wang, A., and Kurahashi, K. (2005) Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery. Clin. Exp. Pharmacol. Physiol. 32, 1027-1033.
70. Hanna, C.J., Bach, M.K., Pare, P.D., and Schellenberg, R.R. (1981) Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 290, 343-344.
71. 4. Fundam. Clin. Pharmacol. 1, 433-444.
72. Bäck, M. (2002) Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle. Acta Physiol. Scand. Suppl. 648, 1-55.
73. Rovati, G. and Capra, V. (2007) Cysteinyl-leukotriene receptors and cellular signals. TheScientificWorldJOURNAL 7, 1375-1392.
74. Cracowski, J.L., Stanke-Labesque, F., Sessa, C., Hunt, M., Chavanon, O., Devillier, P., and Bessard, G. (1999) Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein. Can. J. Physiol. Pharmacol. 77, 770-776.
75. Hu, H., Chen, G., Zhang, J.M., Zhang, W.P., Zhang, L., Ge, Q.F., Yao, H.T., Ding, W., Chen, Z., and Wei, E.Q. (2005) Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors. Acta Pharmacol. Sin. 26, 685-690.
76. 2 on isolated human cerebral arteries. Acta Neurochir. 62, 177-185.
77. 4 on human isolated saphenous veins. Br. J. Clin. Pharmacol. 34, 409-414.
78. Allen, S., Dashwood, M., Morrison, K., and Yacoub, M. (1998) Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97, 2406-2413.
79. Zhao, L., Moos, M.P., Grabner, R., Pedrono, F., Fan, J., Kaiser, B., John, N., Schmidt, S., Spanbroek, R., Lotzer, K., Huang, L., Cui, J., Rader, D.J., Evans, J.F., Habenicht, A.J., and Funk, C.D. (2004) The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 10, 966-973.
80. 4 in man. Int. J. Clin. Lab. Res. 27, 178-184.
81. 4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb. Haemost. 76, 99-104.
82. 4: a role for mediation of interleukin 1. Atherosclerosis 113, 11-18.
83. Palmberg, L., Claesson, H.E., and Thyberg, J. (1987) Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle cells. J. Cell Sci. 88, 151-159.
84. Palmberg, L., Lindgren, J.A., Thyberg, J., and Claesson, H.E. (1991) On the mechanism of induction of DNA synthesis in cultured arterial smooth muscle cells by leukotrienes. Possible role of prostaglandin endoperoxide synthase products and platelet-derived growth factor. J. Cell Sci. 98, 141-149.
85. Kondo, K., Umemura, K., Ohmura, T., Hashimoto, H., and Nakashima, M. (1998) Suppression of intimal hyperplasia by a 5-lipoxygenase inhibitor, MK-886: studies with a photochemical model of endothelial injury. Thromb. Haemost. 79, 635-639.
86. Nomoto, A., Mutoh, S., Hagihara, H., and Yamaguchi, I. (1988) Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis 72, 213-219.
87. Hansson, G.K. (2005) Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695.
88. Jawien, J., Gajda, M., Rudling, M., Mateuszuk, L., Olszanecki, R., Guzik, T.J., Cichocki, T., Chlopicki, S., and Korbut, R. (2006) Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36, 141-146.
89. 4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22, 443-449.
90. 4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 24, 369-375.
91. Hoffmann, R. and Mintz, G.S. (2000) Coronary in-stent restenosis - predictors, treatment and prevention. Eur. Heart J. 21, 1739-1749.
92. Brezinski, D.A., Nesto, R.W., and Serhan, C.N. (1992) Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86, 56-63.
93. Provost, P. and Merhi, Y. (1996) BW755C, a dual lipoxygenase/ cyclooxygenase inhibitor, reduces mural platelet and neutrophil deposition and vasoconstriction after angioplasty injury in pigs. J. Pharmacol. Exp. Ther. 277, 17-21.
94. Provost, P., Borgeat, P., and Merhi, Y. (1998) Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor. Br. J. Pharmacol. 123, 251-258.
95. Luscher, T.F., Steffel, J., Eberli, F.R., Joner, M., Nakazawa, G., Tanner, F.C., and Virmani, R. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115, 1051-1058.
96. 4 induced hyperadhesiveness of endothelial cells for neutrophils. J. Immunol. 152, 262-269.
97. Hui, Y., Cheng, Y., Smalera, I., Jian, W., Goldhahn, L., Fitzgerald, G.A., and Funk, C.D. (2004) Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110, 3360-3366.
98. 4. Proc. Natl. Acad. Sci. U. S. A. 103, 6913-6918.
99. Mita, H., Hasegawa, M., Saito, H., and Akiyama, K. (2001) Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin. Exp. Allergy 31 1714-1723.
100. Zhang, W.P., Hu, H., Zhang, L., Ding, W., Yao, H.T., Chen, K.D., Sheng, W.W., Chen, Z., and Wei, E.Q. (2004) Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci. Lett. 363, 247-251.
101. Datta, Y.H., Romano, M., Jacobson, B.C., Golan, D.E., Serhan, C.N., and Ewenstein, B.M. (1995) Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92, 3304-3311.
102. 4 on bovine aortic endothelial cell proliferation in vitro. Prostaglandins 33, 531-538.
103. 4 binding sites on cultured human keratinocytes. Br. J. Dermatol. 119, 275-280.
104. 4 binding units in cultured bovine aortic endothelial cells. J. Immunol. 137, 1985-1992.
105. Massoumi, R. and Sjölander, A. (2007) The role of leukotriene receptor signaling in inflammation and cancer. TheScientificWorldJOURNAL 7, 1413-1421.
106. Ibe, B.O. and Campbell, W.B. (1988) Synthesis and metabolism of leukotrienes by human endothelial cells: influence on prostacyclin release. Biochim. Biophys. Acta 960, 309-321.
107. 2 activity. J. Biol. Chem. 261, 10713-10718.
108. Clark, M.A., Littlejohn, D., Mong, S., and Crooke, S.T. (1986) Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: release of prostacyclin. Prostaglandins 31, 157-166.
109. Cramer, E.B., Pologe, L., Pawlowski, N.A., Cohn, Z.A., and Scott, W.A. (1983) Leukotriene C promotes prostacyclin synthesis by human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 80, 4109-4113.
110. Pologe, L.G., Cramer, E.B., Pawlowski, N.A., Abraham, E., Cohn, Z.A., and Scott, W.A. (1984) Stimulation of human endothelial cell prostacyclin synthesis by select leukotrienes. J. Exp. Med. 160, 1043-1053.
111. 4 induced formation of inositol phosphate and prostacyclin in human umbilical vein endothelial cells. J. Cell Physiol. 177, 103-108.
112. 2 biosynthesis in human endothelial cells. Biochem. Biophys. Res. Commun. 117, 780-787.
113. Norel, X. (2007) Prostanoid receptors in the human vascular wall. TheScientificWorldJOURNAL 7, 1359-1374.
114. Kiss, L., Schutte, H., Mayer, K., Grimm, H., Padberg, W., Seeger, W., and Grimminger, F. (2000) Synthesis of arachidonic acid-derived lipoxygenase and cytochrome P450 products in the intact human lung vasculature. Am. J. Respir. Crit. Care Med. 161, 1917-1923.
115. 4 in neonates with hypoxemia and pulmonary hypertension. N. Engl. J. Med. 309, 77-80.
116. Galie, N., Torbicki, A., Barst, R., Dartevelle, P., Haworth, S., Higenbottam, T., Olschewski, H., Peacock, A., Pietra, G., Rubin, L.J., Simonneau, G., Priori, S.G., Garcia, M.A., Blanc, J.J., Budaj, A., Cowie, M., Dean, V., Deckers, J., Burgos, E.F., Lekakis, J., Lindahl, B., Mazzotta, G., McGregor, K., Morais, J., Oto, A., Smiseth, O.A., Barbera, J.A., Gibbs, S., Hoeper, M., Humbert, M., Naeije, R., and Pepke-Zaba, J. (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 25, 2243-2278.
117. Jones, J.E., Walker, J.L., Song, Y., Weiss, N., Cardoso, W.V., Tuder, R.M., Loscalzo, J., and Zhang, Y.Y. (2004) Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am. J. Physiol. Heart. Circ. Physiol. 286, H1775-H1784.
118. Bäck, M., Walch, L., Norel, X., Gascard, J.P., Mazmanian, G., and Brink, C. (2002) Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol. Scand. 174, 9-15.
119. Ortiz, J.L., Gorenne, I., Cortijo, J., Seller, A., Labat, C., Sarria, B., Abram, T.S., Gardiner, P.J., Morcillo, E., and Brink, C. (1995) Leukotriene receptors on human pulmonary vascular endothelium. Br. J. Pharmacol. 115, 1382-1386.
120. Larsson, A.-K., Bäck, M., Hjoberg, J., and Dahlén, S.E. (2005) Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J. Pharmacol. Exp. Ther. 315, 458-465.
121. 4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc. Natl. Acad. Sci. U. S. A. 83, 2204-2208.
122. Uzonyi, B., Lotzer, K., Jahn, S., Kramer, C., Hildner, M., Bretschneider, E., Radke, D., Beer, M., Vollandt, R., Evans, J.F., Funk, C.D., and Habenicht, A.J. (2006) Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 103, 6326-6331.
123. 4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc. Natl. Acad. Sci. U. S. A. 81, 2191-2193.
124. 4 are mediated by leukocytic adhesion protein CD18. Scand. J. Immunol. 31, 737-744.
125. 4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156, 2264-2272.
126. 4-triggered monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 23, 1761-1767.
127. 1 receptor-mediated mechanism. J. Pharmacol. Exp. Ther. 281, 655-662.